Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14712598.2020.1796963 http://scihub22266oqcxt.onion/10.1080/14712598.2020.1796963 32744917!ä!32744917 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Biol+Ther 2020 ; 20 (9): 1033-1046 Nephropedia Template TP {{tp|p=32744917|t=2020. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects |pdf=|usr=}}{{32744917}} gab.com Text Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects JO: Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32744917 #FOAvip INTRODUCTION: Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential. AREAS COVERED: This review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients. EXPERT OPINION: In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19. Twit Text FOAVip Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects ????Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32744917 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32744917 #FOAvip English Wikipedia <ref>{{Cite pmid|32744917}}</ref> Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects #MMPMID32744917 Sharun K; Tiwari R; Iqbal Yatoo M; Patel SK; Natesan S; Dhama J; Malik YS; Harapan H; Singh RK; Dhama K Expert Opin Biol Ther 2020[Sep]; 20 (9): 1033-1046 PMID32744917show ga INTRODUCTION: Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential. AREAS COVERED: This review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients. EXPERT OPINION: In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19. |*Betacoronavirus[MESH] |Antibodies, Neutralizing/therapeutic use[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/blood/immunology/therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Immunoglobulins, Intravenous/immunology/*therapeutic use[MESH] |Immunotherapy/*methods/trends[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/blood/immunology/therapy[MESH]Antibody-based immunotherapeutics and use of convalescent plasma to co(epmc).pdf DeepDyve Pubget Overpricing